ADORA3 (Adenosine A3 Receptor), also known as A3AR or ADORA3, encodes the adenosine A3 receptor, a member of the G protein-coupled receptor (GPCR) superfamily that plays critical roles in modulating cellular responses to adenosine in both peripheral tissues and the central nervous system[@fredholm2001]. This receptor has emerged as a significant therapeutic target for neurodegenerative diseases due to its unique signaling properties and expression patterns in the brain[@borea2015].
The adenosine A3 receptor is distinguished from other adenosine receptor subtypes (A1, A2A, A2B) by its ability to couple primarily to Gi/o proteins, leading to inhibition of adenylate cyclase and reduced cAMP production[@chen2013]. This signaling pathway mediates diverse biological effects including modulation of neuroinflammation, protection against oxidative stress, regulation of autophagy, and preservation of neuronal viability under pathological conditions[@gessi2016].
| Property |
Value |
| Gene Symbol |
ADORA3 |
| Gene Name |
Adenosine A3 Receptor |
| Aliases |
A3AR, ADORA3, ADORA3, A3R |
| Chromosomal Location |
1p13.2 |
| NCBI Gene ID |
128 |
| UniProt ID |
P0DP23 |
| Ensembl ID |
ENSG00000121879 |
| Gene Type |
G Protein-Coupled Receptor (GPCR) |
| Protein Class |
Class A Rhodopsin-like |
| Transcript Variants |
3 principal isoforms |
¶ Protein Structure and Pharmacology
ADORA3 possesses the characteristic seven-transmembrane domain architecture common to all GPCRs[@fredholm2001]:
- Seven transmembrane domains (TM1-TM7): Form the core of the receptor and mediate ligand binding
- Extracellular loops (ECL1-ECL3): Contain glycosylation sites and contribute to ligand recognition
- Intracellular loops (ICL1-ICL3): Couple to G proteins and contain regulatory phosphorylation sites
- C-terminal tail: Contains serine/threonine residues for phosphorylation and β-arrestin recruitment
¶ Ligand Binding Properties
The adenosine A3 receptor exhibits distinct pharmacological characteristics:
- High affinity for adenosine: KD ≈ 1-10 nM for endogenous ligand
- Selective agonists: Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine), IB-MECA
- Selective antagonists: MRS1523 (3-propyl-6-ethyl-5-[(ethylamino)carbonyl]-2-phenylpyridine), VUF5574
- Allosteric modulators: Several allosteric binding sites have been identified
The receptor demonstrates species-dependent pharmacology, with notable differences between human and rodent A3 receptors that must be considered in preclinical drug development[@borea2015].
ADORA3 mediates its effects through multiple interconnected signaling pathways[@gessi2016]:
- Adenylate cyclase inhibition: Gi/o protein coupling reduces cAMP production
- MAPK pathway modulation: ERK1/2, p38, and JNK pathways are affected
- PI3K/Akt pathway: Involved in cell survival signaling
- PLC activation: Some coupling to phospholipase C has been reported
- Receptor phosphorylation recruits β-arrestin proteins
- β-arrestin-mediated signaling contributes to receptor function
- Internalization via β-arrestin-dependent mechanisms
| Pathway |
Effect |
Relevance to Neurodegeneration |
| cAMP↓ |
Reduced PKA activity |
Neuroprotective |
| ERK1/2 |
Context-dependent |
May promote survival |
| p38 MAPK |
Anti-inflammatory |
Reduces neuroinflammation |
| Akt |
Pro-survival |
Anti-apoptotic |
| NF-κB |
Inhibited |
Anti-inflammatory |
ADORA3 exhibits a distinctive expression pattern in the central nervous system[@lu2016]:
- Neurons: High expression in hippocampal CA1-CA3 regions, cortical layers II-VI, and cerebellar Purkinje cells
- Astrocytes: Moderate expression, particularly in regions adjacent to blood vessels
- Microglia: High expression, especially in activated states
- Oligodendrocytes: Present but at lower levels
In the brain:
This pattern of expression suggests roles in learning, memory, motor coordination, and neuroimmune modulation[@cunha2016].
ADORA3 modulation has significant implications for AD pathogenesis[@huang2021][@yang2020]:
- A3AR activation reduces Aβ-induced neuronal toxicity
- Agonists decrease Aβ production via γ-secretase modulation
- A3AR signaling enhances clearance of Aβ through autophagy
- Neuroinflammation reduction contributes to decreased Aβ accumulation
- A3AR activation attenuates tau hyperphosphorylation
- Reduction of tau aggregation through enhanced autophagy
- Protection against tau-induced synaptic dysfunction
- Modulation of GSK-3β activity (a key tau kinase)
- Suppression of microglial activation
- Reduced pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6)
- Decreased NO and ROS production in glia
- Promotion of anti-inflammatory phenotype (M2 polarization)
- Preservation of synaptic plasticity
- Enhancement of long-term potentiation (LTP)
- Protection against Aβ-induced synaptic loss
- Maintenance of dendritic spine density
ADORA3 represents a promising target for PD therapy[@li2022][@wang2021][@jacobson2017]:
- A3AR agonists protect substantia nigra dopaminergic neurons
- Reduction of MPTP/6-OHDA-induced toxicity
- Enhancement of mitochondrial function
- Protection against α-synuclein toxicity
- Suppression of microglial activation in substantia nigra
- Reduced dopaminergic neuron loss
- Decreased production of inflammatory mediators
- Promotion of microglial deactivation
- A3AR agonism improves motor performance in PD models
- Reduction of gait abnormalities
- Enhancement of spontaneous locomotion
- Potential for disease modification
- A3AR activation reduces alpha-synuclein aggregation
- Enhanced clearance of α-synuclein aggregates
- Protection against α-synuclein-induced neurodegeneration
- Modulation of autophagy-lysosomal pathway
- A3AR agonism protects motor neurons
- Modulation of neuroinflammation
- Potential for combined therapeutic strategies
- Protection against mutant huntingtin toxicity
- Enhancement of autophagy
- Reduced neuroinflammation
¶ Multiple Sclerosis and Demyelinating Diseases
- A3AR agonists reduce demyelination
- Promotion of remyelination
- Suppression of autoimmune responses[@yu2023]
- A3AR activation provides neuroprotection
- Reduction of infarct size
- Improved functional recovery
- Anti-apoptotic effects
Selective A3AR agonists have shown promise in preclinical and clinical settings[@muller2019][@baraldi2019]:
¶ Clinical Candidates
-
Cl-IB-MECA: Most widely studied A3AR agonist
- Neuroprotective in multiple models
- Entered clinical trials for inflammatory conditions
- Favorable safety profile
-
IB-MECA: Earlier generation agonist
- Demonstrated efficacy in PD models
- Tested in clinical trials for hepatitis and asthma
-
N6-(3-iodobenzyl) derivatives: Newer optimized compounds
- Improved selectivity
- Enhanced brain penetration
- Better pharmacokinetic properties
- Direct neuroprotection via receptor activation
- Anti-inflammatory effects in the CNS
- Enhancement of neurotrophic factor production
- Promotion of neurogenesis
While less explored, A3AR antagonists may have therapeutic potential[@fard2019]:
- May modulate adenosine tone in specific contexts
- Potential for combination therapies
- Utility in understanding receptor biology
Allosteric targeting offers advantages[@volpini2017]:
- Greater subtype selectivity possible
- More nuanced pharmacological effects
- Potential for biased signaling
- Reduced side effects
Several clinical trials are investigating A3AR-targeted therapies:
| Phase |
Compound |
Indication |
Status |
| I/II |
CF101 (Cl-IB-MECA) |
Rheumatoid arthritis, psoriasis |
Completed |
| I/II |
CF102 |
Hepatitis C, dry eye |
Completed |
| Preclinical |
Novel agonists |
PD, AD |
Active |
¶ Challenges and Opportunities
Challenges[@yang2022]:
- Achieving adequate brain penetration
- Managing species differences in receptor pharmacology
- Balancing efficacy and side effects
- Long-term safety concerns
Opportunities:
- Disease modification potential
- Combination with other therapeutic strategies
- Personalized medicine approaches
- Novel delivery systems
| Protein/Pathway |
Interaction Type |
Functional Consequence |
| Gi/o proteins |
G protein coupling |
Adenylate cyclase inhibition |
| β-arrestin |
Scaffold |
Receptor internalization, signaling |
| GRK2/3 |
Phosphorylation |
Receptor desensitization |
| JNK3 |
Interaction |
Pro-survival signaling |
| Akt |
Downstream |
Cell survival |
| NF-κB |
Inhibition |
Anti-inflammatory |
- A3AR knockout mice: Available for mechanistic studies
- Conditional knockouts: For tissue-specific deletion
- Transgenic models: For overexpression studies
- Agonists: Cl-IB-MECA, IB-MECA, 2-Cl-Ado
- Antagonists: MRS1523, VUF5574, OT-7979
- Radioligands: [125I]AB-MECA for binding studies
- Biased signaling: Developing agonists that selectively activate beneficial pathways
- Gene therapy: AAV-mediated A3AR overexpression
- Cell-penetrant peptides: Targeted delivery strategies
- Combination therapies: Synergistic approaches with other targets
- Biomarkers: Identifying predictive markers for patient selection
- Brain-penetrant, selective A3AR agonists
- Long-term safety data in neurodegenerative populations
- Understanding of A3AR's complex signaling in different disease stages
- Optimal dosing and treatment regimens
- Fredholm BB et al, International Union of Pharmacology: adenosine receptors (2001)
- Borea PA et al, The A3 adenosine receptor: history and perspectives (2015)
- Chen JF et al, Adenosine receptors as drug targets—what are the challenges? (2013)
- Gessi S et al, Adenosine receptors in neurodegenerative disorders (2016)
- Cunha RA, How does adenosine control neuronal dysfunction and neurodegeneration? (2016)
- Bours MJ et al, P2X7 and P2Y receptors as regulators of ATP-induced inflammation (2011)
- Lu Y et al, Expression and distribution of adenosine A3 receptor in rat brain (2016)
- Huang L et al, A3 adenosine receptor activation ameliorates neuronal death (2021)
- Yang H et al, A3 adenosine receptor agonism promotes neurogenesis in AD (2020)
- Li X et al, Targeting adenosine A3 receptor for Parkinson's disease therapy (2022)
- Wang J et al, A3 adenosine receptor agonist protects dopaminergic neurons (2021)
- Müller CE et al, A3 adenosine receptor agonists: patent review 2009-2018 (2019)
- Jacobson KA et al, Adenosine A3 receptor as a novel target for PD (2017)
- Stockwell J et al, Adenosine A1 and A3 receptors in the brain (2017)
- Yu L et al, A3 adenosine receptor agonists attenuate neuroinflammation (2023)
- Chen X et al, Role of adenosine signaling in microglial activation (2021)
- Fard SG et al, Selective A3 adenosine receptor agonists and antagonists (2019)
- Volpini R et al, Structure-activity relationships at adenosine receptors (2017)
- Baraldi PG et al, A3 adenosine receptor agonists: from lead optimization (2019)
- Khalili M et al, Adenosine A3 receptor in cell-based therapies for PD (2021)
- Yang L et al, Emerging therapeutic strategies targeting adenosine receptors (2022)